ArticleAnnals of vascular surgery2026
Temporal Trends in Open Revascularization for Aortoiliac Occlusive Disease.
Article in Annals of vascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAortobifemoral bypass grafting (AOFBG) and axillobifemoral bypass grafting (AXFBG) are two options for open reconstruction of severe aortoiliac occlusive disease (AIOD). Historically, AOFBG has been considered the gold standard operation for such patients. However, individuals with multiple prior abdominal operations and those deemed too high risk for an open abdominal operation may be better suited for an extra-anatomic bypass. With the advancement of endovascular interventions, these surgical procedures are increasingly being replaced with aortoiliac stenting as the first line of treatment. Now, AOFBG and AXFBG are generally reserved as second-line options, following failure of an endovascular intervention. Understanding characteristics of those who ultimately undergo AOFBG versus AXFBG can provide insights into changing clinical practice patterns and changing operative experience for vascular trainees.
methodsWe conducted a retrospective analysis using the National Surgical Quality Improvement Program data from 2016 to 2022 to evaluate trends in AOFBG and AXFBG procedures in patients with peripheral artery disease. We used descriptive statistics to examine patient demographics and comorbidities as well as frequency of AOFBG versus AXFBG to assess changes in the utilization of these procedures over time. Logistic regression models were used to evaluate factors associated with undergoing AOFBG versus AXFBG.
resultsFrom 2016 to 2022, the annual volume of AOFBG procedures declined sharply, while AXFBGvolume decreased more modestly. Patients undergoing AXFBG were significantly older than those undergoing AOFBG (68.3 vs. 61.5 years), and the proportion of male patients was higher in the AOFBG group (60.4% vs. 54.2%). Racial distribution differed significantly, with a higher proportion of White patients in the AOFBG group (69.7% vs. 65%). In addition to demographics, the AOFBG versus AXFBG groups differed significantly in baseline comorbidities, where current smoking, hypertension, cancer, dialysis dependence, chronic obstructive pulmonary disease, and CHF were all associated with increased utilization of AXFBG as compared to AOFBG.
conclusionAmong surgical revascularization procedures performed for AIOD, AOFBG demonstrates a greater decrease as compared to AXFBG. However, the differences in baseline characteristics for individuals undergoing AOFBG versus AXFBG still seem to reflect previous practice patterns such that older, sicker patients are more likely to undergo AXFBG. The relatively greater decline in AOFBG may result from the reduction in exposure to open aortic work among vascular surgery trainees and increase in endovascular approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.